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The telomeric repeat-binding factor 1 (TRF1), TRF2,
and the TRF1-interacting nuclear protein 2 (TIN2) are
involved in telomere maintenance. We describe the
regulation of expression of these genes along with
their relationship to telomere length in hepatocarci-
nogenesis. The transcriptional expression of these
genes, TRF1 protein, and telomere length was exam-
ined in 9 normal livers, 14 chronic hepatitis, 24 liver
cirrhosis, 5 large regenerative nodules, 14 low-grade
dysplastic nodules (DNs), 7 high-grade DNs, 10 DNs
with hepatocellular carcinoma (HCC) foci, and 31
HCCs. The expression of TRF1, TRF2, TIN2 mRNA,
and TRF1 protein was gradually increased according
to the progression of hepatocarcinogenesis with a
marked increase in high-grade DNs and DNs with
HCC foci and a further increase in HCCs. There was a
gradual shortening of telomere during hepatocarci-
nogenesis with a significant reduction in length in
DNs. Most nodular lesions (52 of 67) had shorter
telomeres than their adjacent chronic hepatitis or
liver cirrhosis, and the telomere lengths were in-
versely correlated with the mRNA level of these genes
(P < 0.001). This was more evident in DNs and DNs
with HCC foci. In conclusion, TRF1, TRF2, and TIN2
might be involved in multistep hepatocarcinogenesis
by playing crucial roles in telomere shortening. (Am
J Pathol 2005, 166:73–80)
Telomeres, which are located at the end of a chromo-
some, are composed of the 3-end overhang of G-strand,
the double strand of telomeric DNA, and telomere-bind-
ing proteins.1–4 The telomeres stabilize the natural end of
the chromosome, protect it from end-to-end fusion and
mediate chromosome pairing during cell division.5–7
When telomeres reach a critically short length, primary
cells stop dividing and enter senescence. In contrast,
most transformed cells including cancer cells maintain
short but stable telomeres by activating telomerase.
Therefore, the telomere maintenance along with telomer-
ase activation has been suggested as a general mech-
anism of tumorigenesis.8
Telomeres are known to form a loop structure or a
t-loop as a result of an invasion of the single-stranded
G-tail into the double-stranded telomeric tract.9 The telo-
meric repeat-binding factor (TRF) 1 and TRF2 directly
bind to the double-stranded region of the telomere and
play important roles in the t-loop structure.10 Growing
evidence has shown that these proteins are involved in
telomere maintenance by acting as negative regulators.
TRF1 negatively regulates the telomere length by limiting
the access of telomerase to the telomere and mediates
the interaction of the telomere with a mitotic spindle.11,12
TRF2 overexpression leads to the progressive shortening
of the telomere length, and the inhibition of TRF2 induces
growth arrest.13 TRF1-interacting protein 2 (TIN2) co-
localizes with TRF1 in the nucleus. A TIN2 mutant extends
telomeres in telomerase-positive cells,14 suggesting that
TIN2 also controls the telomere length. Manipulation of
the telomere-binding protein gene expression reveals
that alterations in those proteins can impair the function of
the telomere and induce senescence.9,12,14–16 Several
reports have described the up-regulation of TRF1, TRF2,
and TIN2 in lung cancer,17 gastric cancer,18 and that of
TRF2 in lymphomas.19 In contrast, down-regulation of
these genes has been reported in breast cancers,20 gas-
tric cancers,21 and malignant hematopoietic cells.22
Hepatocellular carcinoma (HCC) is the seventh most
common cancer and accounts for the highest number of
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adult malignancies in those areas endemic for the hep-
atitis B virus. There is increasing evidence of a multistep
process in human hepatocarcinogenesis, emphasizing
the preneoplastic nature of large nodules, which are re-
ferred as dysplastic nodules (DNs) or adenomatous hy-
perplasia, usually found in a cirrhotic liver.23 DNs, espe-
cially high-grade DNs, are believed to be preneoplastic
lesions, although the nature of low-grade DNs appears
less resolved than that of high-grade DNs.
Telomere shortening and telomerase activation, which
are important for carcinogenesis, have been observed in
HCCs.24–29 A previous study demonstrated that telomere
shortening and telomerase activation occur in DNs dur-
ing the early stages of hepatocarcinogenesis with a sig-
nificant change in the transition of low-grade DNs to
high-grade DNs.30 However, the expression levels of te-
lomeric repeat-binding proteins as well as their relation-
ship with the telomere length during multistep hepatocar-
cinogenesis have not been examined. To address these
issues, the mRNA levels of TRF1, TRF2, and TIN2, as well
as the TRF1 protein expression level, were examined
using real-time quantitative reverse transcriptase (RT)-
polymerase chain reaction (PCR) and immunohistochem-
istry, respectively, in normal livers, livers with chronic
hepatitis (CH), liver cirrhosis (LC), large regenerative
nodules (LRNs), low-grade DNs, high-grade DNs, DNs
with HCC foci, and HCCs. These mRNAs were subse-
quently compared with the telomere length, which was
measured by Southern hybridization, in multistep hepato-
carcinogenesis, and then with the pathological parameters,
such as the differentiation, mitotic activity, and tumor size of
HCCs.
Materials and Methods
Materials and Pathological Examination
Large nodules, measuring at least 0.5 cm at their largest
dimension, and appearing distinct from the surrounding
cirrhotic parenchyma in terms of their color, texture, and
degree of bulging at the cut surface, HCCs, and the
adjacent nonneoplastic liver tissues were collected from
10 explanted livers and 28 resected specimens. The
patients in this study were 23 males and 15 females with
ages ranging from 32 to 74 years (mean  SD  54.3 
10.03). All patients tested positive to the serum HBsAg
and negative to serum anti-HCV. Half of each nodule was
fixed in 10% buffered formalin, routinely processed, and
embedded in paraffin for a histological examination and
the remaining half of each nodule was retrieved in the
fresh state. The diagnosis of the tissue was confirmed by
examining a frozen-sectioned slide before extraction.
The diagnostic classification of the nodular lesions was
subdivided into the following five groups: 1) LRN, 2)
low-grade DN, 3) high-grade DN, 4) DN with HCC foci,
and 5) HCC according to the standard criteria of an
international working party23 (Figure 1). The pathology of
each nodular lesion was reviewed by two hepatopatholo-
gists (Y.N.P. and C.P.). A total of 67 nodular lesions were
reviewed and there were 5 LRNs, 14 low-grade DNs, 7
high-grade DNs, 10 DNs with HCC foci, and 31 HCCs.
Eleven patients had multiple synchronous nodules rang-
ing from 2 to 11. The differentiation of the HCC was
evaluated according to the Edmondson’s grading sys-
tem. The differentiation of the HCC was grade I in 1,
grade II in 18, and grade III in 12 HCCs. The size of the
HCCs was 5.7  3.98 (mean  SD), ranging from 2 to 16
cm. The rate of mitosis in the HCCs was 10.6 14.83 per
10 high-power fields (mean  SD), ranging from 0 to 60.
The background liver showed hepatitis B virus-related
chronic liver disease, including 14 with CH and 24 with
LC. As controls, nine normal liver tissues were obtained
from the resected liver for benign lesion or metastatic
carcinoma from seven male and two female patients with
ages ranging from 42 to 74 years (mean  SD  58.4 
13.03 years). The controls tested negative for the hepa-
titis virus and showed a relatively normal liver histology,
with the exception of a mild fatty change.
Isolation of Total RNA and Synthesis of cDNA
The frozen tissues were stored in RNAlater (Ambion,
Austin, TX) at 80°C to prevent RNA degradation. The
tissues, weighing 20 to 30 mg, were powdered by grind-
ing with a pestle in liquid nitrogen. The tissue was ho-
mogenized using a Qiashredder (Qiagen, Hilden, Ger-
many), and the total RNA was isolated using a Qiagen
column, according to the manufacturer’s instructions
(Qiagen). The cDNA synthesis was done as previously
described.31 The total RNA (2 g) was pretreated with
RNase-free DNase I (Takara, Shiga, Japan) for 20 min-
utes at 37°C to remove genomic DNA before the cDNA
synthesis. The complete removal of the genomic DNA
was confirmed by a PCR of the total RNA using -actin
primers, which generated no product. The cDNA synthe-
sis was performed in a total volume of 20 l, at 42°C for
50 minutes, containing 1 g of the total RNA, 160 pmol of
the random hexamers (Takara), 200 U of superscript
RNase H reverse transcriptase (Invitrogen, Carlsbad,
CA), 20 U of the RNase inhibitor (Ambion), 0.5 mmol/L
Figure 1. Microscopic feature of human multistep hepatocarcinogenesis
showing low-grade DN (A), high-grade DN with small liver cell dysplasia
(B), DN with HCC foci in bottom right part (C), and HCC with trabecular
pattern (D). H&E; original magnifications, 200.
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dNTP, 10 mmol/L dithiothreitol, and 1 the first strand
buffer (Invitrogen). This was followed by incubation for 15
minutes at 70°C to inactivate the enzyme.
Real-Time Quantitative RT-PCR
The analyses of the TRF1, TRF2, and TIN2 mRNAs were
performed using real-time quantitative RT-PCR, using an
ABI Prism 7700 sequence detection system (Perkin-
Elmer, Emeryville, CA), based on the TaqMan methodol-
ogy. The mRNA expression levels were measured using
the gene-specific fluorescent-labeled probes. Either FAM
or VIC was used as the 5-fluorescent reporters while
TAMRA was added to the 3 end as a quencher. The
primer and probe sequences for TRF1 are as follows:
TRF1 forward primer, 5-TCTCTCTTTGCCGAGCTTTCC-
3; TRF1 reverse primer, 5-ACTGGCAAGCTGTTAGACT-
GGAT-3; TRF1 probe, 5-(FAM) CCCGCAACAGCGCA-
GAGGCTA (TAMRA)-3. For the amplification of TRF2
and TIN2, gene expression products (PE Applied Biosys-
tems, Foster City, CA) were used. The sequence of the
TRF2 and TIN2 primers and probes are under the copy-
right of Applied Biosystems. The 18S rRNA was used to
normalize the sample-to-sample variation in the amount
of the input cDNA, and also to evaluate the quality of the
isolated RNA and RT efficiency. Amplification of the 18S
rRNA was performed using the primers and the internal
probe provided by Perkin-Elmer (PE Applied Biosys-
tems). The standard curve was constructed with fivefold
serial dilutions of the cDNA from the HT1080 cell line,
which corresponded to the total RNA ranging from 0.32 to
200 ng for TRF1, from 0.16 to 100 ng for TRF2, from 0.08
to 50 ng for TIN2, and from 0.008 to 5 ng for 18S rRNA.
The PCR reaction for TRF1 amplification was performed
using 0.5 l of each RT reaction, which corresponded to
25 ng of the total RNA, 1 TaqMan universal master mix
(PE Applied Biosystems), 300 nmol/L of primers, and 200
nmol/L of the probe in a 25-l volume. The PCR reaction
for TRF2 and TIN2 amplification was performed with 0.5
l of each RT reaction, which corresponded to 25 ng of
the total RNA, 1 TaqMan universal master mix (PE
Applied Biosystems), 1 each gene expression products
in a 25-l volume. The 18S rRNA reaction was performed
with 50 nmol/L of the primers, 200 nmol/L of the probe,
and 1 l of the RT reaction, which corresponded to 0.5 ng
of the total RNA. Thermal cycling was initiated with a
2-minute incubation at 50°C, for the uracil N-glycosylase
reaction, which was followed by a 10-minute reaction at
95°C to activate the AmpliTaq gold, and 40 PCR cycles at
95°C for 15 seconds and 60°C for 1 minute. All of the
measurements included a determination of the standards
and no-template as a negative control, in which water
was substituted for the cDNA.
Immunohistochemical Staining for TRF1
Serial sections of each lesion were immunostained with
goat polyclonal anti-TRF1sc-1977 (Santa Cruz Biotech-
nology, Santa Cruz, CA), which recognizes the COOH
terminus of TRF1. The intensity of TRF1 expression was
graded as follows: 0, none; 1, weak; 2, moderate; 3,
strong. The percentage of positive cells was evaluated as
follows: 0, undetectable; 1, less than 10%; 2, 10  50%;
3, more than 50%. The degree of immunopositivity was
obtained by multiplying the intensity and the area of TRF1
expression, and was classified as mild with a score of 1
to 2, moderate with a score of 3 to 5, and marked with a
score of 6 to 9.
Analysis of Telomere Length
The genomic DNA was prepared using the standard
method, with proteinase K treatment and phenol/chloro-
form extraction from 10 to 50 mg of the frozen liver
tissue.30 Two g of the HinfI-digested DNA were fraction-
ated on a 0.7% agarose gel, and transferred to a nylon
membrane using an upward capillary transfer. The hy-
bridization was performed with a 3-end digoxigenin-la-
beled d(TTAGGG)4 (Roche Molecular Biochemicals,
Mannheim, Germany), overnight at 37°C. The hybrids
were detected according to the manufacturer’s recom-
mendation (Roche Molecular Biochemicals). The telo-
mere length was calculated using a previously described
method.32 A mean length of the sample was obtained
from two to three replicate experiments.
Statistical Analysis
The values are expressed as a mean SD. The statistical
analyses were performed using the Mann-Whitney and
linear regression tests where appropriate. A P value
0.05 was considered significant.
Results
Up-Regulation of TRF1, TRF2, and TIN2 in
Human Multistep Hepatocarcinogenesis
The expression levels of TRF1, TRF2, and TIN2 mRNA
were gradually increased according to the progression of
multistep hepatocarcinogenesis and it was also evident
in the patients with multiple synchronous nodules of DNs
and/or HCCs. The results are summarized in Table 1 and
Figure 2. The TRF1 mRNA levels remained low in CH, LC,
and LRNs, which were comparable to those of the normal
liver (Table 1 and Figure 2A). The low- and high-grade
DNs expressed a higher TRF1 mRNA level than CH, LC,
and LRNs (P  0.002) and the mean TRF1 mRNA level of
the DNs was 1.3 times higher than that of the normal
livers. TRF1 mRNA level was further increased in the DNs
with HCC foci compared to the DNs, in which the mean
value was 1.7 times higher than that of the normal livers.
A marked increase was observed in the HCCs (P 
0.005), in which the mean value was 3.2 times higher than
that of the normal livers. The HCCs showed a wide range
of TRF1 mRNA level from 20 to 261, and 29 HCCs (94%)
had a higher TRF1 mRNA level than the adjacent non-
HCCs. According to the differentiation of HCC, those with
poorer differentiation showed a significantly higher level
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of TRF1 mRNA (P  0.004). However, the mitotic activity
and tumor size of HCCs had no correlation with it.
The TRF1 protein expression was evaluated by immu-
nohistochemical staining and it was found in the cyto-
plasm, which is consistent with a previous report.33 The
TRF1 protein expression gradually increased according
to the progression of hepatocarcinogenesis and was well
correlated with the TRF1 mRNA level (P  0.001, R2 
0.422) (Table 2 and Figure 3).
TRF2 mRNA also appeared to increase according to
the progression of multistep hepatocarcinogenesis, par-
ticularly from DNs to HCCs (Table 1 and Figure 2B). The
TRF2 mRNA levels of CH and LC were higher than that of
the normal liver (P  0.019), however, they were still low.
Low-grade DNs showed a TRF2 mRNA level similar to
CH, LC, and LRNs. A significant increase was observed
in the transition of the low-grade DNs to high-grade DNs
(P  0.016) and the mean TRF2 mRNA level of the
high-grade DNs was 2.5 times higher than that of the
normal livers. The DNs with HCC foci had the TRF2
mRNA level similar to high-grade DNs. A further marked
increase was observed in the HCCs (P 0.036), in which
the mean value was 3.4 times higher than that of the
normal livers. The range of TRF2 mRNA level in HCCs
was a rather wide from 9 to 92 and 29 HCCs (94%) had
a higher TRF2 mRNA level than the adjacent non-HCCs.
TRF2 mRNA levels were significantly higher in HCCs with
poorer differentiation (P  0.028) and it was positively
correlated with the mitotic activity of HCCs (P  0.001,
R2 0.347), but had no correlation with the size of HCCs.
The TIN2 mRNA level showed a similar pattern of up-
regulation during multistep hepatocarcinogenesis to
TRF2 mRNA (Table 1 and Figure 2C). CH and LC ex-
pressed TIN2 mRNA at a similarly low level, although their
expression level was higher than that of the normal liver
(P  0.043). Low-grade DNs showed a similar TIN2
mRNA level to that observed in the livers with CH and LC.
A significant increase was noted in the transition from the
low-grade DNs to high-grade DNs (P  0.007) and the
mean value of the high-grade DNs was 2.7 times higher
than the normal livers. A further increase was observed in
the DNs with HCC foci, in which the mean value was 3.2
times higher than that of the normal livers. The HCCs
showed a marked increase in the TIN2 mRNA level (P 
0.026), in which the mean value was 4.3 times higher than
that of the normal livers. All of the HCCs expressed a
higher amount of TIN2 than the adjacent non-HCC, and
their TIN2 mRNA level ranged from 11 to 155. TIN2 mRNA
level showed a positive correlation with mitotic activity of
HCCs (P  0.001, R2  0.424), however it showed no
significant difference according to the differentiation and
size of HCCs. The TRF1, TRF2, and TIN2 mRNA levels
appeared to positively correlate with each other. The
TRF1 mRNA levels were higher in the lesions with higher
TRF2 (P 0.001, R2 0.377) and TIN2 levels (P 0.001,
R2  0.323), and a similar feature was found between
TRF2 and TIN2 (P  0.001, R2  0.547).
Telomere Shortening during Human Multistep
Hepatocarcinogenesis
The normal liver tissues showed telomere lengths ranging
from 8.1 to 9.8 kb, which did not significantly correlate
with the patient ages. A gradual reduction in the telomere
length was observed from the livers with CH, to LC, and
to LRNs (Table 1 and Figure 4). The low-grade DNs had
a wide range of telomere lengths, most of which showed
similar telomere length to those with CH, LC, and LRNs,
and two (14%) of the low-grade DNs had short telomeres,
which overlapped with those of the high-grade DNs. Sig-
nificant telomere shortening occurred in the transition of
the low-grade DNs to high-grade DNs (P  0.020). The
high-grade DNs showed telomere lengths ranging from
4.5 to 8.1 kb, and six (86%) of those had a telomere
length5.4 kb. DNs with HCC foci had telomere length in
the similar range to those of high-grade DNs. The HCCs
had a telomere length with a wide range from 4.7 to 14.3
kb and showed no significant reduction of the telomere
length compared to those of DNs with HCC foci, but most
HCCs (24 of 31, 77%) had shorter telomeres than their
adjacent non-HCCs.
Most nodular lesions (52 of 67, 78%) including 4
LRNs, 11 low-grade DNs, 7 high-grade DNs, 6 DNs
with HCC foci, and 24 HCCs had shorter telomeres
Table 1. Summary of the TRF1, TRF2, and TIN2 mRNA Levels and the Telomere Length in Human Multistep
Hepatocarcinogenesis
TRF1 TRF2 TIN2 Telomere length (kb)
Range Mean  SD Range Mean  SD Range Mean  SD Range Mean  SD
Normal (n  9) 13–42 26  8.5 4–24 10  7.3 3–25 12  8.2 8.1–9.8 8.7  0.57
CH (n  14) 14–48 27  8.8 7–29 17  6.7 7–36 20  9.5 6.8–9.6 8.3  0.94
LC (n  24) 15–39 28  6.4 4–56 17  10.8 5–49 22  10.4 5.6–11.0 7.8  1.19
LRN (n  5) 23–37 30  6.0 7–22 13  5.5 7–15 10  3.0 5.2–9.1 7.8  1.63
LGDN (n  14) 28–47 34  5.9 6–29 14  6.4 7–48 15  11.5 3.9–9.8 7.4  1.77
HGDN (n  7) 25–38 34  4.9 14–41 25  9.4 19–61 32  15.6 4.5–8.1 5.3  1.25
DN with HCC
(n  10)
16–74 44  17.2 9–58 22  14.7 12–65 38  20.2 4.4–8.5 6.4  1.31
HCC (n  31) 20–261 82  47.4 9–92 34  20.2 11–155 51  29.6 4.7–14.3 7.3  2.26
CH, chronic hepatitis; LC, liver cirrhosis; LRN, large regenerative nodule; LGDN, low-grade dysplastic nodule; HGDN, high-grade dysplastic nodule;
DN, dysplastic nodule; HCC, hepatocellular carcinoma.
The TRF1, TRF2, and TIN2 mRNA levels  [target gene mRNA copies of sample/18S rRNA copies of sample]  105.
Telomere length of each tissue was obtained from two- to three replicate experiments.
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than their adjacent CH/LC, whereas some lesions (15
of 67, 22%) including a LRN, 3 low-grade DNs, 4 DNs
with HCC foci, and 7 HCCs had longer telomeres.
Three of the HCCs had telomeres 10 kb. A case of
HCC with a telomere length of 14.3 kb is believed to be
an alternative lengthening of the telomere because it
possessed neither telomerase activity nor hTERT
mRNA (data not shown).
TRF1, TRF2, and TIN2 in Relation to Telomere
Length Regulation
To evaluate whether TRF1, TRF2, and TIN2 are involved
in the telomere length regulation, the mRNA levels of
these genes were compared with the telomere length in
each lesion. All of these genes showed significant neg-
ative correlations with the telomere length, when the anal-
ysis was done with the lesions with shortened telomeres
compared to their respective adjacent CH and LC (note:
this analysis included 4 LRNs, 11 low-grade DNs, 7 high-
grade DNs, 6 DNs with HCC foci, 24 HCCs, and their
respective adjacent CH and LC) (Figure 5). The inverse
correlation was more evident in the early stages of hepa-
tocarcinogenesis including low-grade DNs, high-grade
DNs, and DNs with HCC foci (P 0.036, R2 0.184; P
0.002, R2  0.352; P  0.005, R2  0.308, respectively).
Meanwhile, there was no statistically significant relation-
ship between those genes and the telomere length in the
HCCs, which showed a rather wide range of mRNA levels
of these genes.
The analysis was also performed on the nodular le-
sions with the lengthened telomeres compared to the
respective adjacent CH and LC, which were one LRN,
three low-grade DNs, four DNs with HCC foci, and seven
Figure 2. Comparison of the TRF1, TRF2, and TIN2 mRNA levels in human
multistep hepatocarcinogenesis. The TRF1 (A), TRF2 (B), and TIN2 (C)
mRNA levels are shown in normal livers, CH, LC, LRNs, low-grade dys-
plastic nodules (LGDNs), high-grade dysplastic nodules (HGDNs), DNs
with HCC foci, and HCCs. Eleven patients with multiple synchronous
nodules are denoted by different symbols according to the patient num-
bers (patient 1, black square; patient 2, black diamond; patient 3,
black triangle; patient 4, black circle; patient 5, gray square; patient 6,
gray diamond; patient 7, gray triangle; patient 8, gray circle; patient
9, white square; patient 10, white diamond; patient 11, white triangle;
others, white circle).
Table 2. Semiquantitative Assessment of TRF1 Protein
Expression in Human Multistep
Hepatocarcinogenesis
Mild Moderate Marked
Normal (n  9) 8 1 0
CH (n  14) 11 3 0
LC (n  24) 22 2 0
LRN (n  5) 4 1 0
LGDN (n  14) 8 6 0
HGDN (n  7) 3 4 0
DN with HCC (n  10) 0 8 2
HCC (n  31) 0 4 27
CH, chronic hepatitis; LC, liver cirrhosis; LRN, large regenerative
nodule; LGDN, low-grade dysplastic nodule; HGDN, high-grade dysplastic
nodule; DN, dysplastic nodule; HCC, hepatocellular carcinoma.
Figure 3. Immunoreactivity of TRF1. TRF1 protein expression is mild in CH
(A), moderate in high-grade dysplastic nodule (B), and further increased in
DN with HCC foci (C) with the marked expression in HCC (D). Notice that
increased TRF1 protein expression with the progression of human multistep
hepatocarcinogenesis. Original magnifications, 200.
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HCCs. Most of these lesions also expressed higher levels of
TRF1, TRF2, and TIN2 mRNA compared to the respective
adjacent CH and LC. However, the mRNA levels of these
genes did not show a significant correlation with the telo-
mere length in the lesions with elongated telomeres.
Discussion
In this study, up-regulation of TRF1, TRF2, and TIN2
mRNA levels was observed according to the progression
of human multistep hepatocarcinogenesis, particularly
from DNs to HCCs. A similar expression pattern was
observed in TRF1 protein. To evaluate whether up-regu-
lation of these genes is a common pathway in hepato-
carcinogenesis regardless of its etiology, their mRNA
levels were examined in seven HCCs related to hepatitis
C virus or alcohol and their adjacent non-HCCs (data not
shown). This analysis showed a similar up-regulation of
these genes in the HCCs compared to their adjacent
non-HCCs, which indicates that TRF1, TRF2, and TIN2
up-regulation might be a general mechanism of hepato-
carcinogenesis.
This study demonstrated progressive telomere short-
ening according to the progression of hepatocarcinogen-
esis. Most (78%, 52 of 67) of the nodular lesions including
LRNs, DNs, and HCCs had shorter telomeres than their
adjacent CH/LC, and the lesions with shorter telomeres
had a higher mRNA expression level of TRF1, TRF2, and
Figure 4. Comparison of the telomere length in human multistep hepatocarci-
nogenesis. A: The telomere length is shown in normal livers, CH, LC, LRNs,
low-grade dysplastic nodules (LGDNs), high-grade dysplastic nodules
(HGDNs), DNs with HCC foci, and HCCs. The lesions are denoted by different
symbols according to the patient numbers (patient 1, black square; patient 2,
black diamond; patient 3, black triangle; patient 4, black circle; patient 5,
gray square; patient 6, gray diamond; patient 7, gray triangle; patient 8, gray
circle; patient 9, white square; patient 10, white diamond; patient 11, white
triangle; others, white circle. B: A representative result of Southern blot
analysis in various lesions. The genomic DNA, digested with Hinf I, was hybrid-
ized with a digoxigenin-labeled d(TTAGGG4. The mean telomere restriction
fragment length was calculated by a previously described method, 32 using the
Image Gauge software (Fujifilm, Tokyo, Japan). The size markers are indicated
on the right.
Figure 5. Comparison of TRF1, TRF2, and TIN2 mRNA levels with the
telomere length in human multistep hepatocarcinogenesis. The TRF1, TRF2,
and TIN2 mRNA levels are compared with the telomere length, shown in A,
B, and C, respectively. The analysis was performed with the nodular lesions
with shortened telomeres compared to the adjacent CH and LC. This analysis
included 4 LRNs, 11 low-grade dysplastic nodules (DNs), 7 high-grade DNs,
6 DNs with HCC foci, 24 HCCs, and their respective adjacent CH (n 11) and
LC (n  19). CH, LC, and LRNs are indicated with white circles, low- and
high-grade DNs and DNs with HCC foci with black circles, and HCCs with
gray triangles.
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TIN2. This inverse correlation suggested that these te-
lomere-binding proteins play important roles in telomere
shortening during multistep hepatocarcinogenesis.
Moreover, the positive correlations among the expression
levels of these genes suggest their collaboration in telo-
mere shortening. It was proposed that these telomere-
binding proteins act as negative length regulators at the
telomeres.12,14,34–37 During hepatocarcinogenesis, telo-
mere shortening occurred despite telomerase activa-
tion.30 This might be, in part, explained as follows: the
up-regulation of TRF1, TRF2, and TIN2 might be involved
in the stabilization of the telomeres by promoting t-loop
folding. The stabilization of the t-loop structures, which
limits the access of telomerase to the telomeres,36,37
would eventually result in telomere shortening in hepato-
carcinogenesis.
There is growing evidence that DNs are precancerous
lesions.38 Previous studies as well as this study have
demonstrated that many of high-grade DNs have a short
telomere length and a high telomerase activity, which is
similar to those of HCCs. Moreover, some low-grade DNs
also have similar features.30 Considering that telomere
shortening and telomerase activation play a key role in
tumorigenesis, these results suggest that low- and high-
grade DNs are important early lesions in multistep hepa-
tocarcinogenesis. Telomere shortening leads to loss of
telomere capping, chromosomal fusion, and chromo-
somal instability, which generate a variety of aberrant
chromosomes without functional telomeres at the chro-
mosomal ends via a mechanism of breakage-fusion-
bridge cycle, and cells with aberrant chromosomes
would eventually die unless broken chromosome ends
are healed by telomerase.39 Interestingly, telomere re-
duction and telomerase activation are evident in most
early lesions of hepatocarcinogenesis such as high-
grade DNs and DNs with HCC.30 Thus, it is believed that
these lesions maintain an active end-healing mechanism,
thereby they can provide stable and aberrant chromo-
somes. In fact, chromosomal aberration is reported in the
early lesions of hepatocarcinogenesis and HCCs have a
high incidence of chromosomal instability.40 In this study,
a significant increase of TRF1, TRF2, and TIN2 expres-
sion and an inverse correlation between mRNA levels of
these genes and the telomere length were first noted in
DNs during multistep hepatocarcinogenesis. These re-
sults suggest that these telomere-binding proteins are
involved in telomere shortening in the early stages of
hepatocarcinogenesis. Up-regulation of these genes,
therefore, is likely to be crucial for hepatocarcinogenesis
by inducing telomere crisis, a driving force in tumor de-
velopment.39
HCCs showed no further significant telomere shorten-
ing, compared to the high-grade DNs and DNs with HCC
foci. One of the possible explanations for this would be
the expression of strong telomerase in the HCCs.24,25,30
HCCs expressed a high TRF1, TRF2, and TIN2 mRNA
level, and their mean value was more than three to four
times that of the normal livers. The mRNA levels of these
genes showed no significant correlation with telomeres in
HCCs, indicating that the induction of these genes is
unlikely to directly influence telomere shortening in the
HCCs. Their roles on telomere shortening might be
screened by the strong telomerase activity, which is in-
volved in telomere elongation. Therefore, the balance
between the telomere-binding protein expression and
telomerase activation might be crucial for the telomere
maintenance in HCCs. Interestingly, the HCCs with
poorer differentiation or higher mitotic activity expressed
higher mRNA levels of these telomere-binding protein
genes. This suggests that an excess of these genes is
likely to be involved in HCC progression.
Telomere lengthening was also found during hepato-
carcinogenesis. Seven HCCs and eight other nodular
lesions showed an elongated telomere length. It sug-
gests that the mechanism of telomere lengthening is also
involved in hepatocarcinogenesis, even though it is a
minor pathway. Our data on higher levels of TRF1, TRF2,
and TIN2 mRNA in those lesions but no correlation
with telomere length suggest that an excess of these
genes might be required for the association with the
lengthened telomeres rather directly involved in telomere
length regulation.
In conclusion, an up-regulation of TRF1, TRF2, and
TIN2 was observed during multistep hepatocarcinogen-
esis and mRNA levels of these genes inversely correlated
with the telomere length. The negative correlation was
more evident in the DNs and DNs with HCC foci of early
stages of hepatocarcinogenesis in which the telomere
was significantly shortened. These findings suggest that
TRF1, TRF2, and TIN2 are involved in hepatocarcinogen-
esis, particularly in the early stages of hepatocarcinogen-
esis by playing crucial roles in the telomere shortening.
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